Achieve Life Sciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Achieve Life Sciences, Inc. (ACHV) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.91% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-11
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 14.85% decline year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-03-31 was 4.58%, a 14.50% increase year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.00%, a 13.31% increase year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.53%, a 136.91% increase year-over-year.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.93%, a 1.75% decline from fiscal 2024.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.00%, a 11.11% increase from fiscal 2023.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.60%, a 118.18% increase from fiscal 2022.
- Achieve Life Sciences, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 1.65%, a 150.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.91% 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | 3.93% 10-K · filed 2026-03-24 | |||
| 2025-09-30 | 4.31% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.31% 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | 4.58% 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | 4.00% 10-K · filed 2026-03-24 | |||
| 2024-09-30 | 4.00% 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | 4.00% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.00% 10-Q · filed 2025-05-13 | |||
| 2023-12-31 | 3.60% 10-K · filed 2025-03-11 | |||
| 2023-09-30 | 3.60% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 3.60% 10-Q · filed 2024-08-13 | |||
| 2023-03-31 | 3.53% 10-Q · filed 2024-05-09 | |||
| 2022-12-31 | 1.65% 10-K · filed 2024-03-28 | |||
| 2022-09-30 | 1.65% 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | 1.65% 10-Q · filed 2023-08-14 | |||
| 2022-03-31 | 1.49% 10-Q · filed 2023-05-09 | |||
| 2021-12-31 | 0.66% 10-K · filed 2023-03-16 | |||
| 2021-09-30 | 0.64% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 0.61% 10-Q · filed 2022-08-11 | |||
| 2021-03-31 | 0.59% 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | 0.94% 10-K · filed 2022-03-10 | |||
| 2020-09-30 | 1.43% 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 1.43% 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | 1.51% 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | 2.52% 10-K · filed 2021-03-11 | |||
| 2019-09-30 | 2.52% 10-Q · filed 2020-11-12 | |||
| 2019-06-30 | 2.52% 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | 2.56% 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | 2.93% 10-K · filed 2020-03-13 | |||
| 2018-09-30 | 2.93% 10-Q · filed 2019-11-06 | |||
| 2017-12-31 | 1.95% 10-K · filed 2019-03-14 | |||
| 2017-09-30 | 1.95% 10-Q · filed 2018-11-07 | |||
| 2016-12-31 | 1.51% 10-K · filed 2017-02-23 | |||
| 2016-09-30 | 1.51% 10-Q · filed 2016-11-10 | |||
| 2016-06-30 | 1.51% 10-Q · filed 2017-07-31 | |||
| 2016-03-31 | 1.52% 10-Q · filed 2017-05-15 | |||
| 2015-12-31 | 1.76% 10-K · filed 2017-02-23 | |||
| 2015-09-30 | 1.74% 10-Q · filed 2016-11-10 | |||
| 2015-06-30 | 1.76% 10-Q · filed 2016-08-04 | |||
| 2014-12-31 | 1.83% 10-K · filed 2017-02-23 | |||
| 2014-09-30 | 1.83% 10-Q · filed 2015-11-12 | |||
| 2014-06-30 | 1.81% 10-Q · filed 2015-08-13 | |||
| 2014-03-31 | 1.82% 10-Q · filed 2015-05-14 | |||
| 2013-12-31 | 1.25% 10-K · filed 2016-03-09 | |||
| 2013-09-30 | 1.15% 10-Q · filed 2014-10-30 | |||
| 2013-06-30 | 1.16% 10-Q · filed 2014-08-07 | |||
| 2013-03-31 | 1.12% 10-Q · filed 2014-04-30 | |||
| 2012-12-31 | 0.96% 10-K · filed 2015-03-26 | |||
| 2012-09-30 | 0.96% 10-Q · filed 2013-11-07 | |||
| 2012-06-30 | 0.97% 10-Q · filed 2013-08-08 | |||
| 2011-12-31 | 1.70% 10-K · filed 2014-03-11 | |||
| 2011-09-30 | 2.16% 10-Q · filed 2012-11-08 | |||
| 2011-06-30 | 2.39% 10-Q · filed 2012-08-02 | |||
| 2010-12-31 | 2.73% 10-K · filed 2013-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |